BioSpace News Archive

Genetown

The Best Way to Answer Salary Interview Questions

Interviews can be difficult in any field, but especially in a competitive industry like the life sciences. Read on to discover the best way to answer salary interview questions in our guide.

June 11, 2024
·
4 min read
·
Lorenzo Soliman
FDA

Ipsen, Genfit’s Elafibranor Wins FDA Approval for Primary Biliary Cholangitis

Ipsen and Genfit’s elafibranor will now be marketed as Iqirvo and is the first new medicine approved in nearly a decade for the treatment of the rare liver disease, according to the companies.

June 11, 2024
·
2 min read
·
Tristan Manalac
Drug Development

Lilly Sees More Zepbound Out-of-Pocket Payments as Obesity Pill Nears Phase III Readout

More patients are having to pay out-of-pocket for Eli Lilly’s weight-loss medication Zepbound than they did for type 2 diabetes drug Mounjaro, according to Lilly USA President Patrik Jonsson.

June 11, 2024
·
2 min read
·
Tristan Manalac
Policy

GSK Appeals Delaware Court’s Decision in Zantac Cases as Plaintiff Drops Lawsuit

On Monday, GSK reported that a plaintiff voluntarily dropped her Zantac case against the company and that it is in the process of appealing a Delaware State Court’s decision to admit expert testimony in other cases.

June 11, 2024
·
2 min read
·
Tristan Manalac
Business

Stada Bags European Rights from Alvotech to Biosimilar of Amgen Blockbusters

Stada announced Tuesday it has secured European rights from Alvotech to a clinical-stage biosimilar of Amgen’s blockbuster bone drugs Prolia and Xgeva.

June 11, 2024
·
2 min read
·
Nick Paul Taylor
Policy

Who’s Paying for Million-Dollar Gene Therapies?

Given their seven-figure price tags, it’s not clear how accessible the would-be cures will be to U.S. patients on public or private insurance.

June 11, 2024
·
5 min read
·
Karen Fischer
Business

Syntis Bio Launches in Effort to Challenge GLP-1s in Lucrative Weight Loss Market

Seeking to carve out its own niche in the obesity space, Syntis Bio launched on Tuesday to develop an oral weight-loss treatment that mimics the effects of gastric bypass surgery.

June 11, 2024
·
2 min read
·
Tristan Manalac
Policy

Opinion: As More Companies Are Targeted by BIOSECURE Act, Investor Relations Crisis Brews

The House Select Committee asks the FBI for a briefing on GenScript’s links to China, fueling the challenge facing public relations and investor relations teams at US biopharma firms and Chinese CDMOs.

June 11, 2024
·
4 min read
·
JX (Jaxon) Tan
Drug Development

Sage’s Dalzanemdor Shows Effect in Huntington’s Study, Analysts Say Results ‘Underwhelming’

While Sage Therapeutics’ drug candidate showed a slight difference compared to placebo in a mid-stage Huntington’s disease trial, William Blair analysts in a Tuesday note to investors said they “remain cautious” on dalzanemdor and “do not view the small numerical changes as definitive.”

June 11, 2024
·
2 min read
·
Tyler Patchen
Business

The 6 Largest Biopharma Layoffs of 2024 So Far

Despite a surge in the financial markets, multiple Big Pharma companies have announced hundreds or even thousands of cuts. Experts hope for a better second half of the year.

June 11, 2024
·
5 min read
·
Kate Goodwin